Literature DB >> 3894417

Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis.

L Jonasson, J Holm, O Skalli, G Gabbiani, G K Hansson.   

Abstract

A large proportion of the cells of the human atherosclerotic plaque is assumed to be derived from medial smooth muscle cells. In contrast to these, the cells of the plaque have the capacity to accumulate lipid, and they also proliferate at a higher rate than medial cells. It has therefore been suggested that smooth muscle cells undergo a change of phenotype during atherogenesis, but there has been no evidence for such a change on the molecular level. We have now analyzed carotid artery plaques using a battery of antibodies against cell surface and cytoskeletal antigens, and found that most of the cells express the class II transplantation antigen (Ia antigen) HLA-DR. Also, the beta chain of HLA-DR was detected by immunoblotting of plaque extracts with the OKIa1 monoclonal antibody. HLA-DR is normally present on cells of the immune system, but only 60% of the DR-positive cells of the plaque reacted with monoclonal antibodies specific for macrophages and lymphocytes. Many of the remaining DR-positive cells contained the muscle-specific intermediate filament protein, desmin. This indicates that smooth muscle cells of atherosclerotic plaques express DR antigen. In contrast, very few DR-positive cells were found in normal human arteries. This suggests that expression of class II antigen is part of a phenotypic change in smooth muscle cells in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894417      PMCID: PMC423725          DOI: 10.1172/JCI111934

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

Review 1.  Separation and functional analysis of subpopulations of lymphocytes bearing complement and Fc receptors.

Authors:  C R Parish
Journal:  Transplant Rev       Date:  1975

2.  Immunological characterization of the subunit of the 100 A filaments from muscle cells.

Authors:  E Lazarides; B D Hubbard
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

3.  Epidermal Langerhans cells express Ia antigens.

Authors:  L Klareskog; U Tjernlund; U Forsum; P A Peterson
Journal:  Nature       Date:  1977-07-21       Impact factor: 49.962

4.  An improved rosetting assay for detection of human T lymphocytes.

Authors:  M E Kaplan; C Clark
Journal:  J Immunol Methods       Date:  1974-07       Impact factor: 2.303

5.  Selective solubilization of a protein component of the red cell membrane.

Authors:  V T Marchesi; E Steers
Journal:  Science       Date:  1968-01-12       Impact factor: 47.728

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells.

Authors:  G K Hansson; G A Starkebaum; E P Benditt; S M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

Review 8.  Ia antigens: their serology, molecular relationships, and their role in allograft reactions.

Authors:  J Klein; V Hauptfeld
Journal:  Transplant Rev       Date:  1976

9.  Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis.

Authors:  R Ross; J A Glomset
Journal:  Science       Date:  1973-06-29       Impact factor: 47.728

10.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  72 in total

Review 1.  Inflammation in atherosclerosis and diabetes mellitus.

Authors:  Jorge Plutzky
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Quantification of Various Inflammatory Cells in Advanced Atherosclerotic Plaques.

Authors:  Veronica Soundra Veena Paul; Christina Mary Priya Paul; Sarah Kuruvilla
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 3.  Endothelial function and inflammation in coronary artery disease.

Authors:  D Tousoulis; M Charakida; C Stefanadis
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

4.  Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.

Authors:  Giovanna Butticè; Janice Miller; Lin Wang; Barbara D Smith
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

5.  Analysis of adhesion molecules in the immunopathogenesis of giant cell arteritis.

Authors:  S O Wawryk; H Ayberk; A W Boyd; J Rode
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

Review 6.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 7.  How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses.

Authors:  Jillian P Rhoads; Amy S Major
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 8.  Is hypertension an immunologic disease?

Authors:  David G Harrison; Tomasz J Guzik; Jorg Goronzy; Cornelia Weyand
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

9.  Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway.

Authors:  S Christen; S R Thomas; B Garner; R Stocker
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 10.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.